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In Brief
Henty-Ridilla et al. demonstrate that the actin-binding protein profilin directly enhances microtubule growth rate in vitro and in cells. These stimulatory effects on microtubules are unaffected by mutations in profilin disrupting its actin functions and instead rely on surface residues of profilin mutated in ALS patients.
SUMMARY
Profilin is an abundant actin monomer-binding protein with critical actin regulatory roles in vivo [1, 2] . However, profilin also influences microtubule dynamics in cells, which may be mediated in part through its interactions with formins that in turn bind microtubules [3, 4] . Specific residues on human profilin-1 (PFN1) are mutated in patients with amyotrophic lateral sclerosis (ALS) [5, 6] . However, the observation that some ALSlinked PFN1 mutants fail to alter cellular actin organization or dynamics [5] [6] [7] [8] or in vitro actin-monomer affinity [9] has been perplexing, given that profilin is best understood as an actin regulator. Here, we investigated direct effects of profilin on microtubule dynamics and whether ALS-linked mutations in PFN1 disrupt such functions. We found that human, fly, and yeast profilin homologs all directly enhance microtubule growth rate by several-fold in vitro. Microtubule stimulatory effects were unaffected by mutations in the canonical actin-or poly-proline-binding sites of profilin. Instead, microtubule activities depended on specific surface residues on profilin mutated in ALS patients. Furthermore, microtubule effects were attenuated by increasing concentrations of actin monomers, suggesting competition between actin and microtubules for binding profilin. Consistent with these biochemical observations, a 2-fold increase in the expression level of wild-type PFN1, but not the ALS-linked PFN1 mutants, increased microtubule growth rates in cells. Together, these results demonstrate that profilin directly enhances the growth rate of microtubules. They further suggest that ALS-linked mutations in PFN1 may perturb cellular microtubule dynamics and/or the coordination between the actin and microtubule cytoskeletons, leading to motor neuron degeneration.
RESULTS AND DISCUSSION
Profilin is an abundant cytosolic protein with two canonical binding sites, one for actin monomers and one for poly-L-proline (PLP) tracts found in key actin regulators such as formins and Ena/VASP [10] [11] [12] [13] [14] [15] . Through these two interactions, profilin enhances the growth rate of actin filaments [1, 16, 17] and plays a critical role in distributing monomers between different actin nucleation systems [2, 13, 14, 18, 19] . In addition to its well-established roles in regulating actin dynamics, profilin can influence microtubule (MT) organization and dynamics in vivo [4, 20] . Further, tubulin and MT-associated proteins have been identified as potential profilin binding partners on affinity columns [19] , and profilin has been visualized on the sides of MTs in cells using immunofluorescence following extraction to remove unbound cytosolic profilin [4] . Recent in vivo studies suggest that some of these MT regulatory effects may be indirect, mediated by interactions between profilin and formins, which in turn bind MTs [4, 20, 21] . However, whether profilin has direct effects MT dynamics remains an open question.
Human Profilin Directly Enhances the Growth Rate of Microtubules In Vitro
We used total internal reflection fluorescence (TIRF) microscopy to compare MT dynamics in the presence and absence of purified human profilin-1 (PFN1) (Figures 1A and 1B ; Movie S1). In control reactions, MTs exhibited hallmark characteristics of MT dynamic instability, stochastically transitioning between phases of steady growth and rapid shortening ( Figure 1A ). Addition of 5 mM PFN1 led to a 4.5-fold increase in MT growth rate ( Figures 1B and 1C ) but did not change the average time MTs spent growing ( Figure 1D ). Consistent with an increased growth rate, MTs had increased lengths before undergoing catastrophe in the presence of PFN1 ( Figure 1E ). PFN1 did not significantly change the frequency of MT catastrophe or rescue events and therefore did not substantially alter MT stability index (ratio of rescue to catastrophe events) ( Figure 1F ). Enhancement of MT growth was saturated at PFN1 concentrations R5 mM, which is well within the physiological concentration range of profilin (Figures 1G and S1A-S1E) [16, 19] .
PFN1 also altered the rate of MT elongation over a range of tubulin concentrations (1-30 mM) (Figures 1H and S1F-S1J). From these observations, we calculated that PFN1 increases the on rate of tubulin at MT ends by as much as 4.6-fold (from 3,526 to 16,315 tubulin dimers min À1 mM À1 ). At 5 mM tubulin, significant growth from MT seeds was observed only in the presence of PFN1 ( Figure 1I ), suggesting that PFN1 also may lower the critical concentration for tubulin polymerization. Consistent with these effects on MT dynamics, purified PFN1 bound to See also Figure S1 and Movies S1 and S2.
MTs in a concentration-dependent manner with an affinity (K d = 10.7 ± 2.3 mM) that is predicted to readily support binding at physiological concentrations of profilin and tubulin ( Figure 1J ). Under these same experimental conditions, PFN1 and MTs colocalized by immunofluorescence, supporting a direct interaction ( Figures 1K and 1L ). Attempts to reengineer profilin surface cysteines to enable fluorescence labeling compromised MT stimulatory functions, precluding live-imaging of profilin interacting with MTs in vitro.
We also compared the effects on MTs of purified human PFN1, S. cerevisiae profilin (Pfy1), and D. melanogaster profilin (Chickadee). Each profilin homolog had similar effects on average MT growth rate and length (Figures 1M and S1K-S1O; Movie S2), demonstrating that MT interactions are conserved among evolutionarily distant members of the profilin family.
ALS-Linked Mutations in Human Profilin Disrupt Microtubule Interactions In Vitro
We next asked whether the MT stimulatory effects of PFN1 are disrupted by mutations in the conserved binding sites for actin monomers (R88E) or poly-L-proline motifs (Y6D) ( Figures  2A and 2B ) [8] . Both mutants were indistinguishable from wild-type PFN1 in stimulating MT growth (Figures 2B and S1P-S1T). Thus, neither canonical binding site is required for MT interactions. This led us to consider whether surfaces on profilin mutated in ALS might be involved in regulating MT dynamics [5, 6] . The ALS-linked mutations in PFN1 are dominant in patients, and their expression over endogenous PFN1 in cultured primary neurons results in ALS-like phenotypes, including increased stress granule formation [22] , impaired neurite outgrowth [5, 7] , and motor neuron degeneration [7] . It has remained an open question how some PFN1 mutations (i.e., M114T and G118V) promote neurodegeneration without altering cellular morphology, actin cytoskeleton dynamics [5, 7, 8] , or in vitro actin monomer binding affinity [9] .
We purified four ALS-linked PFN1 mutants (M114T, E117G, G118V, and H120E) that are less prone to aggregation compared to mutations such as C71G [5, 7, 9, [22] [23] [24] . Among these mutants, only one (H120E) has shown defects in actin monomer binding [5, 9, 25] . Using in vitro TIRF microscopy assays, two mutants (M114T and G118V) completely failed to enhance MT growth, and a third (E117G) exhibited partial defects in stimulating MT growth ( Figures 2C, 2D , and S2A). Similar to wild-type PFN1, the mutants did not alter any other parameters of MT dynamics ( Figures 2E, 2F , and S2B-S2D). Additionally, M114T and G118V both failed to bind MTs, suggesting that their inability to stimulate MT growth stems from a loss of MT binding affinity. However, the E117G and H120E mutants bound to MTs with affinities similar to wild-type PFN1 ( Figures 2G, 2H , S2E, and S2F). Therefore, the partial defects of E117G in stimulating MT growth do not appear to stem from a simple loss of MT affinity ( Figures 2G and 2H ), but rather a mechanistic defect in MT regulation that we do not yet understand. Because H120E was indistinguishable from wildtype PFN1 in its ability to bind and enhance MT growth, this mutant appears to be impaired specifically in actin binding. An examination of the positions of the MT-defective ALS mutations on PFN1 (M114T, E117G, and G118V) revealed that together they form a surface-exposed patch that is adjacent to, but not overlapping with the actin-binding surface ( Figure 2A ).
Profilin Effects on Microtubules Are Sensitive to the Presence of Actin Monomers
To further investigate the relationship between the interaction of profilin with MTs and actin, we asked whether PFN1 stimulation of MT growth in vitro is affected by increasing concentrations of actin monomers maintained in a monomeric state by Latrunculin-A ( Figures 3A and 3B ). Latrunculin-A binds to monomeric actin near the nucleotide-binding pocket and does not overlap with the profilin binding footprint on actin [26] . In the presence of 2.5 and 5 mM monomeric actin, 5 mM PFN1 continued to promote MT growth similar to control reactions lacking actin (Figure 3B ). However, with 10 mM actin monomers present, PFN1 effects on MT growth were decreased, and with 15 mM actin monomers, the effects of PFN1 on MTs were strongly inhibited. Importantly, the presence of actin only affected those parameters of MT dynamics regulated by PFN1 in the absence of actin (i.e., MT elongation rate and length) (Figures 3B and S3A-S3D). As expected, the Y6D mutant PFN1, which binds normally to actin, had MT regulatory effects sensitive to actin monomers, similar to wild-type PFN1 ( Figure 3C ). In contrast, the R88E mutant, which is defective in actin binding, stimulated MT growth in a manner that was insensitive to actin monomers ( Figure 3D ). The M114T and G118V mutants of PFN1 failed to enhance MT growth on their own, or in the presence of actin monomers (Figures 3E and 3F ). The E117G mutant showed a modest increase in sensitivity to actin monomer levels compared to wild-type PFN1 ( Figure 3G ), consistent with its partial defects in MT regulation. Finally, the H120E mutant was almost completely insensitive to actin monomers, consistent with its defects in actin binding ( Figure 3H) .
Altogether, these dose-response effects ( Figure 3I ) suggest there is competition between MTs and actin monomers for binding profilin, and this agrees well with the close proximity of the MT and actin-binding sites on profilin (Figure 2A) . Further, the observation that half-maximal MT stimulatory effects occurred at equal molar concentrations of tubulin and actin (10 mM each) indicates that profilin has a similar effective concentration range for influencing MTs and actin, consistent with a role in coordinating MT and actin dynamics in cells.
Profilin Increases the Growth Rate of Microtubules in Cells
To test the biological relevance of these observations, we asked whether a modest increase in expression levels of PFN1 alters MT dynamics in mouse neuroblastoma (N2A) cells. Expression of PFN1 led to 2-fold higher levels of PFN1 compared to control cells, as indicated by both quantitative immunofluorescence ( Figures S4A-S4C ) and quantitative western blot ( Figure S4D ). The overall fluorescence levels of actin filaments (F-actin) and MTs were not significantly different compared to control cells ( Figures S4E and S4F ), indicating that cytoskeletal architecture is not grossly altered by elevated PFN1 expression. However, quantitative tracking of MT plus ends ( Figures 4A and 4B ) revealed an almost 3-fold increase in the average velocity of MT plus ends in cells expressing wild-type PFN1 ( Figure 4B ). This change in MT dynamics occurred without a change in total MT polymer levels, indicating that PFN1 alters MT dynamics in cells without significantly changing the fraction of tubulin in polymer. Similar results were observed for increased expression of the actin-binding impaired R88E mutant ( Figure 4B ). These results mirror our in vitro observations and demonstrate that profilin can increase MT growth rates in cells.
Next, we investigated the effects of elevated PFN1 expression on filopodial extension, a process regulated by MT-actin crosstalk [27] [28] [29] . Using live cell imaging to simultaneously monitor MT plus-ends (EB1-GFP) and actin filaments (mCherry-Utrophin), we examined the effects of PFN1 on MT penetrance into filopodia, average number of filopodia per cell, and filopodial stability ( Figures 4C-4F ). Wild-type PFN1 expression led to a significant increase in MT entry into filopodia ( Figure 4D) , as well as an increase in the number of filopodia per cell ( Figure 4E ) and average filopodial lifetime ( Figure 4F ). Expression of R88E PFN1 led to an increase in filopodia number similar to wild-type PFN1, but elicited an even greater increase in MTs entering filopodia and average filopodial lifetime. These results suggest that the loss of actin binding in the R88E mutant may cause additional cytoskeletal defects that impact filopodial formation and stability, (H) Inset: western blots of cell extracts were used to determine relative PFN1 and a-tubulin levels for ALS-associated PFN1 mutants and controls. Quantification of band intensities from western blots of PFN1 levels (gray) and a-tubulin levels (teal) (n = 3 blots per treatment). Error bars represent SE. (I) Live-cell TIRF microscopy of EB1-GFP comets was used to track MT plus-ends from control or cells with enhanced levels of PFN1 or PFN1 mutations associated with ALS (n = 50-193 cells per condition). (J) Model for the distribution of profilin toward regulating actin or MTs. MTs, actin, and actin nucleators (formins and the Arp2/3 complex) compete for profilin. Thus, profilin is a molecular oscillator capable of regulating the dynamics of individual MTs, the availability of actin monomers to specific actin nucleation systems, and due to competition for profilin between MTs and actin monomers, acts as a regulator of actin-MT crosstalk. All experiments were performed at least three independent times. Error bars indicate 95% confidence intervals. Significant differences by one-way ANOVA with Bartlett's correction for variance: ns, not significantly different from control; a, compared with control (p < 0.05); b, compared with wild-type PFN1 (p < 0.05). See also Figure S4 and Movie S3.
possibly through profilin-formin interactions affecting the MT cytoskeleton [4, 21] .
Our results demonstrate that a modest increase in PFN1 expression increases MT growth rates in N2A cells. However, a recent study showed that RNAi silencing of PFN1 in B16 melanoma cells also increases MT plus end velocities [4] . At first glance, these two observations seem to be at odds with each other. For this reason, we tested the effects of PFN1 silencing in our own system (Figures S4G-S4L) . Similar to the results from B16 cells, we found that depletion of PFN1 in N2A cells led to an increase in MT velocity, albeit not to the same extent as cells with increased PFN1 expression ( Figure 4G ). Thus, MT growth rates appear to be highly sensitive to PFN1 levels in either direction, with either a >5-fold reduction in PFN1 or a $2-fold increase in PFN1 producing faster MT growth rates. The increase in MT velocity in cells with slightly elevated PFN1 can be readily explained by our in vitro data showing that PFN1 directly binds and stimulates MT growth ( Figures 1A and 1B) . The less pronounced increase in MT velocity resulting from PFN1 silencing may be an indirect effect, stemming from the loss of profilin-formin interactions [4] . Therefore, these two effects appear to result from two separate mechanisms.
ALS-Linked Mutations in PFN1 Disrupt Microtubule Stimulatory Effects in Cells
Using the in vivo assays above, we finally asked whether the same ALS mutants defective in stimulating MT growth in vitro are also impaired in stimulating MT growth in cells. We individually expressed in cells the five ALS mutants (C71G, M114T, E117G, G118V, and H120E) and wild-type PFN1 and compared their effects on MT growth using EB1-GFP tracking (Movie S3). In each case, PFN1 levels approximately doubled, as indicated by quantitative immunofluorescence (Figures S4M and S4N ) and western blot analysis ( Figure 4H ). Cellular levels of actin filaments and MTs were not significantly altered by wild-type or ALS mutant PFN1s ( Figure S4O ). Further, no difference in the total cellular tubulin levels was observed ( Figures 4H and  S4P ), demonstrating that increased MT growth rates are not the result of higher tubulin concentrations. MT growth rates were enhanced similarly by wild-type PFN1 and the H120E mutant, which is impaired in actin binding ( Figure 4I ). C71G showed slightly weaker enhancement of MT growth, consistent its propensity to aggregate ( Figure 4I ) [7, 9] . M114T, E117G, and G118V were all impaired in stimulating MT growth, consistent with their in vitro activities ( Figure 4I ). Thus, our in vitro and in vivo observations are in good agreement showing that wildtype PFN1 promotes MT growth, whereas specific ALS-linked mutants are defective in these novel activities.
Conclusions
In vivo effects of profilin on MT dynamics and organization have been reported in systems ranging from mammalian cells to green algae and the protist T. cruzi [2, 30, 31] . Here, we demonstrated direct biochemical effects of human, yeast, and fly profilin homologs on MT dynamics, with each one enhancing the growth rate of MTs by several fold. In addition, we found that a modest 2-fold increase in the level of human profilin enhances MT growth rates, and these in vitro and in vivo effects on MT dynamics are disrupted by mutations in PFN1 linked to ALS. The MT regulatory residues form a surface patch on profilin, which is distinct from, but adjacent to, the actin-binding surface. This proximity of these sites may explain why increasing levels of actin monomers competitively attenuate the stimulatory effects of PFN1 on MTs and why PFN1 mutants that impair actin-binding (R88E and H120E) render MT stimulatory effects unresponsive to actin monomers addition. Profilin and tubulin are both highly abundant in the cytosol, with estimated concentrations above 10 mM [32] , making profilin well suited for governing cellular MT dynamics. Until now, estimations of the free versus actin monomer-bound fractions of profilin in cells have only considered competition with thymosin-b4 for actin monomer binding and have not considered the reciprocal possibility of factors competing with actin monomers for profilin binding. Our work reveals a competitive relationship between actin and MTs in binding profilin; therefore, a substantial fraction of profilin in cells may be bound to MTs. Indeed, tubulin and microtubule-associated proteins are among the major factors isolated from brain extracts on profilin affinity columns [19] . Further, a recent study showed that stabilization of the actin cytoskeleton with Jasplakinolide, which decreases actin monomer levels, increased PFN1 association with MTs in cells by immunofluorescence [4] .
Profilin interactions in living cells may be more complex than previously appreciated ( Figure 4J ), and our data suggest that profilin not only mediates crosstalk between different actin nucleation systems [13, 14, 33] , but also between MT and actin polymer systems. At present, we do not have a good assay for testing whether endogenous profilin influences MT dynamics through the direct mechanism we have reported. However, we observed strong stimulatory effects on MT growth rate in vitro at concentrations of MTs, profilin, and non-sequestered actin monomers close to estimated cellular conditions. Even though the cytosol of vertebrate cells contains $100 mM actin monomers, most of this pool is bound to thymosin-b4, potentially increasing the cytosolic concentration of free profilin available to regulate MTs.
Our results also offer new insights into how specific ALSlinked mutations in PFN1 ultimately lead to motor neuron degeneration. We showed that three conserved residues on PFN1 mutated in ALS patients, which have little effect on PFN1-actin interactions [9, 10] , (M114, E117, and G118), are critically involved in enhancing MT growth both in vitro and in cells. These results suggest that the progressive degeneration of motor neurons in ALS patients with these mutations may result from changes in the MT cytoskeleton. Further, they add to an increasing body of evidence suggesting that various defects in MT dynamics and MT-dependent axonal transport lead to motor neuron degeneration in ALS [34] , including those caused by mutations in dynein, kinesin, and tubulin itself [35, 36] . In addition, some of the more common ALS-linked mutations such as in the RNA processing proteins TDP43 and FUS alter MT-dependent mRNA transport along motor neuron axons, and mutations in the ALS risk factor VEGF reduce the levels of MT-stabilizing microtubule-associated proteins [37] ., Additionally, mutations in SOD1, which cause approximately twenty percent of all familial ALS cases, result in hyper-dynamic MTs and impaired axonal transport. Moreover, these defects are ameliorated by pharmacological stabilization of MT dynamics [38] . Thus, it is becoming increasingly apparent that MTs are a site of convergence in ALS, impacted by diverse genetic insults linked to the disease, and chemically targeting MTs may be an effective approach for combating the lethality of ALS.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Recombinant Human Profilin-1 (PFN1), and mutations, were expressed in E. coli BL21(DE3) cells and purified as previously described [11] . The immortalized neuroblastoma (N2A) cell line, derived from a male mouse, was obtained directly from ATCC and used to examine the biological effects of wild-type and ALS-relevant mutations in PFN1 on actin and microtubules in cells. N2A cells were grown at 37 C with 5% CO 2 in DMEM supplemented with 200 mM L-glutamine and 10% FBS.
METHOD DETAILS Reagents
All materials were obtained from Sigma-Aldrich (St. Louis, MO) unless noted.
Protein purification
Proteins were purified and/or fluorescently labeled as described below. Tubulin [43] was purified from freshly obtained Bovine brains by three cycles of temperature-induced polymerization and depolymerization. Brains were rinsed in 1 3 PBS, then mixed with one volume depolymerization buffer (50 mM MES (pH 6.6), 1 mM CaCl 2 ), homogenized in a blender, and precleared by centrifugation at 29,000 3 g for 1 h at 4 C. To polymerize tubulin, one volume of HMPB (1 M PIPES (pH 6.9), 10 mM MgCl 2 , 20 mM EGTA, 10 mM DTT) was added to the supernatant, along with a final concentration of 1.5 mM ATP and 0.5 mM GTP, and 1/3 volume of glycerol. This mixture was incubated at 37 C for 1 h, and then microtubules (MTs) were pelleted by centrifugation at 151,000 3 g for 30 min at 37 C. To depolymerize the MTs, the pellets were resuspended in cold depolymerization buffer, and incubated on ice for 30 min, then precleared at 70,000 3 g for 30 min at 4 C. The supernatant was harvested, and polymerization and depolymerization steps were repeated two more times, for a total of three cycles. On the final cycle, depolymerziation was carried out in cold BRB80 buffer (80 mM PIPES (pH 6.8), 1 mM MgCl 2 , 1 mM EGTA), and then the tubulin was precleared at 104,000 3 g for 30 min at 4 C, aliquoted, and frozen in liquid nitrogen. To label tubulin with AlexaFluor-647 [43, 44] , polymerized MTs were incubated with a 20-fold molar excess of dye for 30 min at 37 C in labeling buffer (0.1 M NaHEPES (pH 8.6), 1 mM MgCl 2 , 1 mM EGTA, 40% (v/v) glycerol). The reaction was then quenched with 2 3 BRB80 supplemented with 100 mM C 5 H 8 KNO 4 and 40% (v/v) glycerol. Excess dye was removed by performing two cycles of MT polymerization/depolymerization as above, and then aliquoted and stored in M2B (80 mM PIPES (pH 6.8), 2 mM MgCl 2 , 1 mM EGTA) at À80 C. AlexaFluor-647 GMP-CPP MT seeds [44] were polymerized by combining 15 mM unlabeled tubulin, 7.5 mM AlexaFluor-647 tubulin, and 0.5 mM GpCpp (Jenna Bioscience, Jena, Germany) and incubating for 30 min at 37 C. MT seeds were collected by centrifugation and resuspended in 1 3 BRB80, aliquoted, and stored at À80 C. Wild-type human and ALS mutant Profilin1 proteins [11] were expressed in BL21(DE3) cells. Cells were grown to OD 600 = 0.5 at 37 C, then induced with IPTG for 3 h at 37 C. Pellets were resuspended in 50 mM Tris HCl (pH 8.0) and DNase I, and sonicated at 4 C. The cell lysate was clarified by centrifugation at 20,000 3 g. The supernatant was passed over at QHighTrap column (GE Healthcare, Marlborough, MA) equilibrated in 50 mM Tris-HCl (pH 8.0), 1 M KCl, and the flow-through (containing Profilin) was collected and then applied to a Superdex 75 (10/300) gel filtration column (GE Healthcare) equilibrated in 50 mM Tris (pH 8.0), 50 mM KCl. Fractions containing Profilin were pooled, aliquoted, and stored at À80 C. Thawed Profilin aliquots were pre-cleared at 279,000 3 g before use.
Rabbit skeletal muscle actin (RMA) [45] was purified from acetone powder, generated from frozen ground hind leg muscle tissue from young rabbits (PelFreez, Rogers, AR). Lyophilized acetone powder stored at À80 C was mechanically sheered in a chilled coffee grinder, resuspended in G-buffer (3 mM Tris-HCl (pH 8.0), 0.5 mM DTT, 0.2 mM ATP, 0.1 mM CaCl 2 ), and then cleared by centrifugation at 50,000 3 g. Actin was polymerized from the supernatant overnight at 4 C by addition of 2 mM MgCl 2 and 0.5 mM ATP. F-actin was pelleted by centrifugation at 361,000 3 g, and then depolymerized by dounce homogenization and dialysis against 
